Some in vitro and in vivo studies suggested that multimerin 2 may reduce tumour angiogenesis and growth by interfering with the vascular endothelial growth factor (VEGF-A/VEGFR2) pathway thus making it a potential candidate in developing cancer treatment [16, 20]. The gene discussed is MMRN2; the disease is cancer.